Platelet aggregation in focal cerebral ischemia - a clinical study

Publisher Website
Google Scholar
Abstract
In a consecutive series of 35 patients with transient ischemic attacks (TIA) 26 patients (74%) had pathological platelet aggregation 4 wk after the latest TIA. Pathological platelet aggregation was the most frequent factor leading to a prophylactic treatment of the TIA. Among 12 patients with reversible ischemic neurological deficit (RIND), only 1 had pathological platelet aggregation, and among 54 patients with completed stroke, 37% had pathological platelet aggregation 4 wk after the cerebral infarction. It is possible by the antiaggregating agents acetylsalicylic acid and dipyridamole to normalize in vitro pathological platelet aggregation. The frequency of side effects was low. During this treatment further TIA was stopped in 17/19 patients and remission was seen in 14/14 stroke patients. Compared with the remissions during treatment with anticoagulants, there was a tendency of more favorable outcome in the group of stroke patients when treated with antiaggregating agents.